Targeting Signaling Pathways in T-cell acute lymphoblastic leukemia initiating cells

Advances in Biological Regulation

Volumn 56, Issue , 2014, Pages 6-21

  Martelli, Alberto M ^a   Lonetti, Annalisa ^a   Buontempo, Francesca ^a   Ricci, Francesca ^b   Tazzari, Pier Luigi ^b   Evangelisti, Camilla ^c,d   Bressanin, Daniela ^a   Cappellini, Alessandra ^e   Orsini, Ester ^a   Chiarini, Francesca ^c,d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c CNR   (Italy)

^d RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^e UNIVERSITY OF CASSINO AND SOUTHERN LAZIO   (Italy)

Author keywords

Notch1; PI3K Akt mTOR; Relapse; T ALL; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TARGET OF RAPAMYCIN KINASE;

ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASTIC STEM CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84906729585     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2014.04.004     Document Type: Article

References (128)

1. Agliano A., Martin-Padura I., Mancuso P., Marighetti P., Rabascio C., Pruneri G., et al. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2R γ null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer 2008, 123:2222-2227.
2. Agnusdei V., Minuzzo S., Frasson C., Grassi A., Axelrod F., Satyal S., et al. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia 2014, 28:278-288.
3. Aifantis I., Raetz E., Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008, 8:380-390.
4. Ailles L.E., Gerhard B., Kawagoe H., Hogge D.E. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 1999, 94:1761-1772.
5. Anderson K., Lutz C., van Delft F.W., Bateman C.M., Guo Y., Colman S.M., et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469:356-361.
6. Armstrong F., Brunet de la Grange P., Gerby B., Rouyez M.C., Calvo J., Fontenay M., et al. NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood 2009, 113:1730-1740.
7. Aster J.C., Pear W.S., Blacklow S.C. Notch signaling in leukemia. Annu Rev Pathol 2008, 3:587-613.
8. Bandapalli O.R., Zimmermann M., Kox C., Stanulla M., Schrappe M., Ludwig W.D., et al. NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. Haematologica 2013, 98:928-936.
9. Bellavia D., Campese A.F., Checquolo S., Balestri A., Biondi A., Cazzaniga G., et al. Combined expression of pTα and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc Natl Acad Sci USA 2002, 99:3788-3793.
10. Bhojwani D., Pui C.H. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol 2013, 14:e205-217.
11. Blackburn J.S., Liu S., Raiser D.M., Martinez S.A., Feng H., Meeker N.D., et al. Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency. Leukemia 2012, 26:2069-2078.
12. Blackburn J.S., Liu S., Wilder J.L., Dobrinski K.P., Lobbardi R., Moore F.E., et al. Clonal evolution enhances leukemia-propagating ell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation. Cancer Cell 2014, 25:366-378.
13. Bressanin D., Evangelisti C., Ricci F., Tabellini G., Chiarini F., Tazzari P.L., et al. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. Oncotarget 2012, 3:811-823.
14. Buontempo F., Orsini E., Martins L.R., Antunes I., Lonetti A., Chiarini F., et al. Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling. Leukemia 2014, 28:543-553.
15. Capaccione K.M., Pine S.R. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis 2013, 34:1420-1430.
16. Chiang M.Y., Xu L.W., Shestova O., Histen G., L'Heureux S., Romany C., et al. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. JClin Invest 2008, 118:3181-3194.
17. Chiarini F., Fala F., Tazzari P.L., Ricci F., Astolfi A., Pession A., et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res 2009, 69:3520-3528.
18. Chiarini F., Grimaldi C., Ricci F., Tazzari P.L., Evangelisti C., Ognibene A., et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 2010, 70:8097-8107.
19. Chiu P.P., Jiang H., Dick J.E. Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance. Blood 2010, 116:5268-5279.
20. Ciofani M., Zuniga-Pflucker J.C. Notch promotes survival of pre-T cells at the β-selection checkpoint by regulating cellular metabolism. Nat Immunol 2005, 6:881-888.
21. Ciofani M., Zuniga-Pflucker J.C. Asurvival guide to early T cell development. Immunol Res 2006, 34:117-132.
22. Clappier E., Gerby B., Sigaux F., Delord M., Touzri F., Hernandez L., et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. JExp Med 2011, 208:653-661.
23. Cox C.V., Evely R.S., Oakhill A., Pamphilon D.H., Goulden N.J., Blair A. Characterization of acute lymphoblastic leukemia progenitor cells. Blood 2004, 104:2919-2925.
24. Cox C.V., Martin H.M., Kearns P.R., Virgo P., Evely R.S., Blair A. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood 2007, 109:674-682.
25. Crews L.A., Jamieson C.H. Selective elimination of leukemia stem cells: hitting a moving target. Cancer Lett 2013, 338:15-22.
26. Della Gatta G., Palomero T., Perez-Garcia A., Ambesi-Impiombato A., Bansal M., Carpenter Z.W., et al. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. Nat Med 2012, 18:436-440.
27. Duan J.J., Qiu W., Xu S.L., Wang B., Ye X.Z., Ping Y.F., et al. Strategies for isolating and enriching cancer stem cells: well begun is half done. Stem Cells Dev 2013, 22:2221-2239.
28. Eisterer W., Jiang X., Christ O., Glimm H., Lee K.H., Pang E., et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 2005, 19:435-441.
29. Ellisen L.W., Bird J., West D.C., Soreng A.L., Reynolds T.C., Smith S.D., et al. Tan-1, the human homolog of the drosophila Notch gene, is broken by chromosomal translocations in T-lymphoblastic neoplasms. Cell 1991, 66:649-661.
30. Evangelisti C., Ricci F., Tazzari P., Tabellini G., Battistelli M., Falcieri E., et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 2011, 25:781-791.
31. Fayard E., Moncayo G., Hemmings B.A., Hollander G.A. Phosphatidylinositol 3-kinase signaling in thymocytes: the need for stringent control. Sci Signal 2010, 3:re5.
32. Ferrando A.A., Neuberg D.S., Staunton J., Loh M.L., Huard C., Raimondi S.C., et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002, 1:75-87.
33. Fogelstrand L., Staffas A., Wasslavik C., Sjogren H., Soderhall S., Frost B.M., et al. Prognostic implications of mutations in NOTCH1 and FBXW7 in childhood T-all treated according to the NOPHO ALL-1992 and ALL-2000 protocols. Pediatr Blood Cancer 2014, 61:424-430.
34. Franke T.F. PI3K/Akt: getting it right matters. Oncogene 2008, 27:6473-6488.
35. Fre S., Huyghe M., Mourikis P., Robine S., Louvard D., Artavanis-Tsakonas S. Notch signals control the fate of immature progenitor cells in the intestine. Nature 2005, 435:964-968.
36. Gachet S., Genesca E., Passaro D., Irigoyen M., Alcalde H., Clemenson C., et al. Leukemia-initiating cell activity requires calcineurin in T-cell acute lymphoblastic leukemia. Leukemia 2013, 27:2289-2300.
37. Garnier J.M., Sharp P.P., Burns C.J. BET bromodomain inhibitors: a patent review. Expert Opin Ther Pat 2014, 24:185-199.
38. Gerby B., Clappier E., Armstrong F., Deswarte C., Calvo J., Poglio S., et al. Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations. Leukemia 2011, 25:1249-1258.
39. Giambra V., Jenkins C.R., Wang H., Lam S.H., Shevchuk O.O., Nemirovsky O., et al. NOTCH1 promotes T cell leukemia-initiating activity by RUNX-mediated regulation of PKC-θ and reactive oxygen species. Nat Med 2012, 18:1693-1698.
40. Golde T.E., Koo E.H., Felsenstein K.M., Osborne B.A., Miele L. γ-Secretase inhibitors and modulators. Biochim Biophys Acta 2013, 1828:2898-2907.
41. Gordon W.R., Roy M., Vardar-Ulu D., Garfinkel M., Mansour M.R., Aster J.C., et al. Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL. Blood 2009, 113:4381-4390.
42. Greystoke B.F., Huang X., Wilks D.P., Atkinson S., Somervaille T.C. Very high frequencies of leukaemia-initiating cells in precursor T-acute lymphoblastic leukaemia may be obscured by cryopreservation. Br J Haematol 2013, 163:538-541.
43. Guo W., Lasky J.L., Chang C.J., Mosessian S., Lewis X., Xiao Y., et al. Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature 2008, 453:529-533.
44. Guo W., Schubbert S., Chen J.Y., Valamehr B., Mosessian S., Shi H., et al. Suppression of leukemia development caused by PTEN loss. Proc Natl Acad Sci USA 2011, 108:1409-1414.
45. Gutierrez A., Grebliunaite R., Feng H., Kozakewich E., Zhu S.Z., Guo F., et al. Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. JExp Med 2011, 208:1595-1603.
46. Gutierrez A., Sanda T., Grebliunaite R., Carracedo A., Salmena L., Ahn Y.B., et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 2009, 114:647-650.
47. Hadnagy A., Gaboury L., Beaulieu R., Balicki D. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 2006, 312:3701-3710.
48. Hales E.C., Orr S.M., Larson Gedman A., Taub J.W., Matherly L.H. Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells. JBiol Chem 2013, 288:22836-22848.
49. Hales E.C., Taub J.W., Matherly L.H. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell Signal 2014, 26:149-161.
50. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
51. Hoshii T., Kasada A., Hatakeyama T., Ohtani M., Tadokoro Y., Naka K., et al. Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells. Proc Natl Acad Sci USA 2014, 111:3805-3810.
52. Inaba H., Greaves M., Mullighan C.G. Acute lymphoblastic leukaemia. Lancet 2013, 381:1943-1955.
53. Inaba H., Pui C.H. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol 2010, 11:1096-1106.
54. Indraccolo S., Minuzzo S., Masiero M., Pusceddu I., Persano L., Moserle L., et al. Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy. Cancer Res 2009, 69:1314-1323.
55. Ito M., Kobayashi K., Nakahata T. NOD/Shi-scid IL2r γ(null) (NOG) mice more appropriate for humanized mouse models. Curr Top Microbiol 2008, 324:53-76.
56. Jenkinson S., Koo K., Mansour M.R., Goulden N., Vora A., Mitchell C., et al. Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial. Leukemia 2013, 27:41-47.
57. Jhanwar-Uniyal M., Jeevan D., Neil J., Shannon C., Albert L., Murali R. Deconstructing mTOR complexes in regulation of glioblastoma multiforme and its stem cells. Adv Biol Regul 2013, 53:202-210.
58. Jotta P.Y., Ganazza M.A., Silva A., Viana M.B., da Silva M.J., Zambaldi L.J.G., et al. Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia 2010, 24:239-242.
59. Kaminski M., Kiessling M., Suss D., Krammer P.H., Gulow K. Novel role for mitochondria: protein kinase Ctheta-dependent oxidative signaling organelles in activation-induced T-cell death. Mol Cell Biol 2007, 27:3625-3639.
60. Kang S.A., Pacold M.E., Cervantes C.L., Lim D., Lou H.J., Ottina K., Gray N.S., Turk B.E., Yaffe M.B., Sabatini D.M. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science 2013, 341:1236566.
61. Karrman K., Forestier E., Heyman M., Andersen M.K., Autio K., Blennow E., et al. Clinical and cytogenetic features of a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias: rare T-cell receptor gene rearrangements are associated with poor outcome. Genes Chromosomes Cancer 2009, 48:795-805.
62. King B., Trimarchi T., Reavie L., Xu L., Mullenders J., Ntziachristos P., et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 2013, 153:1552-1566.
63. Klco J.M., Spencer D.H., Miller C.A., Griffith M., Lamprecht T.L., O'Laughlin M., et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 2014, 25:379-392.
64. Knoechel B., Roderick J.E., Williamson K.E., Zhu J., Lohr J.G., Cotton M.J., et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet 2014, 46:364-370.
65. Koch U., Lehal R., Radtke F. Stem cells living with a Notch. Development 2013, 140:689-704.
66. Koch U., Radtke F. Notch in T-ALL: new players in a complex disease. Trends Immunol 2011, 32:434-442.
67. + cells and contribute to their leukemogenic transformation. JBiol Chem 2013, 288:18219-18227.
68. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. Acell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
69. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
70. Laplante M., Sabatini D.M. Regulation of mTORC1 and its impact on gene expression at a glance. JCell Sci 2013, 126:1713-1719.
71. Lee J., Beliakoff J., Sun Z. The novel PIAS-like protein hZimp10 is a transcriptional co-activator of the p53 tumor suppressor. Nucleic Acids Res 2007, 35:4523-4534.
72. Lee K., Nam K.T., Cho S.H., Gudapati P., Hwang Y., Park D.S., et al. Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia. JExp Med 2012, 209:713-728.
73. - cell population with intrinsic resistance to imatinib. Blood 2009, 114:5191-5200.
74. Lleo A. Activity of γ-secretase on substrates other than APP. Curr Top Med Chem 2008, 8:9-16.
75. Lobry C., Oh P., Aifantis I. Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. JExp Med 2011, 208:1931-1935.
76. Lonetti A., Antunes I.L., Chiarini F., Orsini E., Buontempo F., Ricci F., et al. Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia. Leukemia 2013, doi:10.1038/leu.2013.369, 10.1038/leu2013.369.
77. Luis T.C., Ichii M., Brugman M.H., Kincade P., Staal F.J. Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development. Leukemia 2012, 26:414-421.
78. Ma W.X., Gutierrez A., Goff D.J., Geron I., Sadarangani A., Jamieson C.A.M., et al. NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches. Plos One 2012, 7:e39725.
79. Magee J.A., Ikenoue T., Nakada D., Lee J.Y., Guan K.L., Morrison S.J. Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell 2012, 11:415-428.
80. Magee J.A., Piskounova E., Morrison S.J. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012, 21:283-296.
81. Maillard I., Weng A.P., Carpenter A.C., Rodriguez C.G., Sai H., Xu L.W., et al. Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood 2004, 104:1696-1702.
82. Martelli A.M., Tabellini G., Ricci F., Evangelisti C., Chiarini F., Bortul R., et al. PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy. Adv Biol Regul 2012, 52:214-227.
83. Masiero M., Minuzzo S., Pusceddu I., Moserle L., Persano L., Agnusdei V., et al. Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells. Leukemia 2011, 25:588-598.
84. Mavrakis K.J., Wolfe A.L., Oricchio E., Palomero T., de Keersmaecker K., McJunkin K., et al. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol 2010, 12:372-379.
85. McCubrey J.A., Steelman L.S., Bertrand F.E., Davis N.M., Abrams S.L., Montalto G., et al. Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia 2014, 28:15-33.
86. Medyouf H., Gao X., Armstrong F., Gusscott S., Liu Q., Gedman A.L., et al. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood 2010, 115:1175-1184.
87. Medyouf H., Gusscott S., Wang H.F., Tseng J.C., Wai C., Nemirovsky O., et al. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. JExp Med 2011, 208:1809-1822.
88. Mullighan C.G., Zhang J., Kasper L.H., Lerach S., Payne-Turner D., Phillips L.A., et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011, 471:235-239.
89. Nguyen L.V., Vanner R., Dirks P., Eaves C.J. Cancer stem cells: an evolving concept. Nat Rev Cancer 2012, 12:133-143.
90. Notta F., Mullighan C.G., Wang J.C., Poeppl A., Doulatov S., Phillips L.A., et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011, 469:362-367.
91. Ortega-Molina A., Serrano M. PTEN in cancer, metabolism, and aging. Trends Endocrin Met 2013, 24:184-189.
92. Paganin M., Ferrando A. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev 2011, 25:83-90.
93. Palomero T., Lim W.K., Odom D.T., Sulis M.L., Real P.J., Margolin A., et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 2006, 103:18261-18266.
94. Palomero T., Sulis M.L., Cortina M., Real P.J., Barnes K., Ciofani M., et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 2007, 13:1203-1210.
95. Pear W.S., Aster J.C., Scott M.L., Hasserjian R.P., Soffer B., Sklar J., et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. JExp Med 1996, 183:2283-2291.
96. Piovan E., Yu J., Tosello V., Herranz D., Ambesi-Impiombato A., Da Silva A.C., et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell 2013, 24:766-776.
97. Pui C.H., Evans W.E. Treatment of acute lymphoblastic leukemia. NEngl J Med 2006, 354:166-178.
98. Rakowski L.A., Garagiola D.D., Li C.M., Decker M., Caruso S., Jones M., et al. Convergence of the ZMIZ1 and NOTCH1 pathways at C-MYC in acute T lymphoblastic leukemias. Cancer Res 2013, 73:930-941.
99. Real P.J., Tosello V., Palomero T., Castillo M., Hernando E., de Stanchina E., et al. γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009, 15:50-58.
100. Rehe K., Wilson K., Bomken S., Williamson D., Irving J., den Boer M.L., et al. Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations. EMBO Mol Med 2013, 5:38-51.
101. Reynolds T.C., Smith S.D., Sklar J. Analysis of DNA surrounding the breakpoints of chromosomal translocations involving the β T cell receptor gene in human lymphoblastic neoplasms. Cell 1987, 50:107-117.
102. Ribeiro D., Melão A., Barata J.T. IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia. Adv Biol Regul 2013, 53:211-222.
103. Roderick J.E., Tesell J., Shultz L.D., Brehm M.A., Greiner D.L., Harris M.H., et al. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood 2014, 123:1040-1050.
104. Rodon J., Dienstmann R., Serra V., Tabemero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013, 10:143-153.
105. Saftig P., Reiss K. The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential?. Eur J Cell Biol 2011, 90:527-535.
106. -/- mice. Methods Mol Biol 2013, 1031:19-26.
107. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22:159-168.
108. Sarmento L.M., Barata J.T. Therapeutic potential of Notch inhibition in T-cell acute lymphoblastic leukemia: rationale, caveats and promises. Expert Rev Anticancer Ther 2011, 11:1403-1415.
109. Shanware N.P., Bray K., Abraham R.T. The PI3K, metabolic, and autophagy networks: interactive partners in cellular health and disease. Annu Rev Pharmacol 2013, 53:89-106.
110. Sharma V.M., Calvo J.A., Draheim K.M., Cunningham L.A., Hermance N., Beverly L., et al. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol 2006, 26:8022-8031.
111. Silva A., Yunes J.A., Cardoso B.A., Martins L.R., Jotta P.Y., Abecasis M., et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. JClin Invest 2008, 118:3762-3774.
112. Takebe N., Nguyen D., Yang S.X. Targeting Notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther 2014, 141:140-149.
113. Tatarek J., Cullion K., Ashworth T., Gerstein R., Aster J.C., Kelliher M.A. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL. Blood 2011, 118:1579-1590.
114. - fraction. Blood 2010, 115:1976-1984.
115. Thompson B.J., Buonamici S., Sulis M.L., Palomero T., Vilimas T., Basso G., et al. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. JExp Med 2007, 204:1825-1835.
116. Toker A. Achieving specificity in Akt signaling in cancer. Adv Biol Regul 2012, 52:78-87.
117. Tosello V., Ferrando A.A. The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy. Ther Adv Hematol 2013, 4:199-210.
118. Trinquand A., Tanguy-Schmidt A., Ben Abdelali R., Lambert J., Beldjord K., Lengline E., et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult t-cell acute lymphoblastic leukemia: a group for research in adult acute lymphoblastic leukemia study. JClin Oncol 2013, 31:4333-4342.
119. Van Vlierberghe P., Ambesi-Impiombato A., De Keersmaecker K., Hadler M., Paietta E., Tallman M.S., et al. Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia. Blood 2013, 122:74-82.
120. Vilimas T., Mascarenhas J., Palomero T., Mandal M., Buonamici S., Meng F., et al. Targeting the NF-κB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007, 13:70-77.
121. Wei P., Walls M., Qiu M., Ding R., Denlinger R.H., Wong A., et al. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 2010, 9:1618-1628.
122. Weng A.P., Ferrando A.A., Lee W., Morris JPt, Silverman L.B., Sanchez-Irizarry C., et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306:269-271.
123. Wolfer A., Wilson A., Nemir M., MacDonald H.R., Radtke F. Inactivation of Notch1 impairs VDJβ rearrangement and allows pre-TCR-independent survival of early αβ Lineage Thymocytes. Immunity 2002, 16:869-879.
124. Wu Y., Cain-Hom C., Choy L., Hagenbeek T.J., de Leon G.P., Chen Y., et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010, 464:1052-1057.
125. Yashiro-Ohtani Y., Ohtani T., Pear W.S. Notch regulation of early thymocyte development. Semin Immunol 2010, 22:261-269.
126. Zenatti P.P., Ribeiro D., Li W.Q., Zuurbier L., Silva M.C., Paganin M., et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet 2011, 43:932-939.
127. Zhou S., Schuetz J.D., Bunting K.D., Colapietro A.M., Sampath J., Morris J.J., et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2011, 7:1028-1034.
128. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011, 12:21-35.